Introduction
VLDL from hypertriglyceridemic (HTG)' subjects and chylomicrons are the only native human plasma lipoproteins reported to cause rapid, massive, receptor-mediated lipid accu-mulation in macrophages in vitro (1) (2) (3) . The macrophage receptor responsible for uptake of human chylomicrons and HTG-VLDL appeared to be distinct from the LDL receptor both functionally (1-3) and genetically (4) . Uptake of these human triglyceride-rich lipoproteins was originally ascribed to the ",B-VLDL receptor" (1) (2) (3) (4) (5) . The f3-VLDL receptor was thought to be distinct from the LDL receptor because original studies demonstrated that receptors of macrophages preincubated in the presence of serum (conditions that downregulate LDL receptor activity in fibroblasts) efficiently mediated uptake of canine ,B-VLDL but not LDL (6) .
Recent studies, however, indicate that the uptake of f,-VLDL by murine macrophages is mediated primarily by the LDL receptor (7, 8) . Macrophages cultured under conditions that maximize LDL receptor activity (cells preincubated in lipoprotein-deficient serum) bound canine ,3-VLDL with high affinity, via apoE, whereas both human and murine LDL bound poorly, indicating the murine macrophage LDL receptor efficiently binds lipoproteins through apoE but not apoB (7) . Likewise, uptake of rat ,B-VLDL and chylomicron remnants by murine peritoneal, P388D,, and J774 macrophages appeared to be mediated primarily by the LDL receptor since uptake was inhibited by anti-LDL receptor antibodies (8) .
Other studies suggest, however, that there are additional receptors on macrophages distinct from the LDL receptor, both functionally and genetically (1) (2) (3) (4) (5) , that bind certain human triglyceride-rich lipoproteins. Receptors present on macrophages with downregulated LDL receptor activity continue to bind human chylomicrons (1) (2) (3) (4) (5) 9) , hypertriglyceridemic very low density lipoproteins Sf 100-400 (HTG-VLDL,) (1) (2) (3) 5) and thrombin-treated HTG-VLDL, (2, 3) with high affinity. Although HTG-VLDL, also bind to LDL receptors with high affinity (10) (11) (12) (13) , neither chylomicrons (14) nor thrombin-treated HTG-VLDL, (10) (11) (12) (13) bind to LDL receptors.
Fogelman, Edwards, and co-workers have reported that macrophages possess receptors for human chylomicrons and rabbit ,B-VLDL that are genetically as well as functionally distinct from the LDL receptor (4, 9, 15) . Monocyte-derived macrophages from a subject with homozygous familial hypercholesterolemia (FH) (4), as well as macrophages (9) and endotheHal cells (15) isolated from the homozygous WHHL rabbit bound human lymph and plasma chylomicrons. Such studies indicate that a macrophage/endothelial cell receptor that binds human chylomicrons is genetically distinct from the LDL receptor (4, 9, 15) .
To facilitate studies of the macrophage receptor for uptake of human plasma chylomicrons and HTG-VLDL, we developed conditions that maximized the expression of this pathway and minimized expression of the LDL receptor pathway in the long-term murine macrophage line P388D1 (2) . When grown on complete serum, P388D1 macrophages express very iow levels of the LDL receptor (2, 16 ) and do not secrete apoE (2) . Secretion of apoE and/or expression of the LDL receptor would introduce ambiguity into the interpretation of the cell studies described in this report, since apoE mediates binding of VLDL Sf 60-400 to the LDL receptor (10) (11) (12) (13) 17) . The characteristics of the pathway for HTG-VLDL uptake by P388D, cells are like those previously described in freshly isolated, unstimulated murine peritoneal macrophages (1, 2) . Competition studies indicated that the macrophage receptor that binds iodinated HTG-VLDL, also binds chylomicrons, HTG-VLDL, and f3-VLDL from cholesterol-fed rabbits, but not LDL or acetyl LDL (2, 3) . Moreover, thrombin-treated HTG-VLDL, which do not bind to LDL receptors in cultured human fibroblasts (I10-12) or ligand blot partially purified bovine LDL receptors (13) , nevertheless compete as well as or better than native HTG-VLDL for the uptake and degradation of iodinated HTG-VLDL1 by murine P388D1 macrophages (2) or peritoneal macrophages (3), suggesting the uptake was not via the LDL receptor.
The studies we now report indicate that macrophages possess receptors for abnormal human triglyceride-rich lipoproteins that are distinct from LDL receptors in ligand specificity, regulation, immunological characteristics, and cellular distribution. A specific macrophage membrane binding protein distinct from the LDL receptor shares these properties and is a candidate for this alternate receptor.
Methods
Cells and cell culture. The murine macrophage cell line P388D1 (Salk Institute Cell Repository, La Jolla, CA) was cultured in RPMI 1640 (high glucose) supplemented with 1% glutamine, 10% fetal bovine serum (Gibco Laboratories, Grand Island, NY), 100 ,gg/ml penicillin, and 100 U/ml streptomycin (2, 18 ). Cells were maintained in 100-mm dishes in a humidified incubator (5% CO2) at 37°C. Human mononuclear cells were isolated from whole blood of a healthy, normal subject by the method of Boyum (19) and placed in tissue culture dishes for 2 h in RPMI 1640 medium containing 20% autologous serum to allow monocytes to adhere (20) . After nonadherent cells were removed, the monocytes were incubated in complete medium for 3 d in a CO2 incubator before study.
For binding and triglyceride accumulation studies, -2 X 105 P388D1 cells were seeded in 2 ml of complete medium into 60 X 15-mm dishes. Cultures were refed 24 h later with complete medium, and on the second day the medium was removed. After washing twice with saline, the cells were incubated in 2 ml of serum-free RPMI 1640 containing the desired concentration of lipoprotein, as indicated in the figures. For ligand blotting studies, -5 X I05 cells were seeded in 10 ml of complete medium in 100 X 15 mm dishes and harvested 24 h later.
For binding, uptake, and degradation studies, duplicate dishes of cells and empty dishes were incubated with labeled lipoproteins alone and in the presence of indicated quantities of unlabeled lipoprotein at 40 or 37°C for up to 4 h as indicated in the figure legends. All experiments are conducted at 2-4 h of incubation in the absence of serum components other than lipoproteins. Total cell-associated radioactivity (representing both surface-bound and internalized) was determined after the cells were washed three times with chilled buffer containing 2 mg albumin/ml and twice with albumin-free buffer (I18). (27) before reisolation by gradient flotation as described above. Each preparation of native HTG-VLDL or of protease-modified HTG-VLDL used in the macrophage studies was also tested for its ability to cause LDL receptor-mediated HMG-CoA reductase suppression in cultured normal human skin fibroblasts, a sensitive measure of LDL receptor determinants present on the lipoprotein (10-12), and/or for its ability to ligand blot partially purified bovine LDL receptors after electrophoresis and transfer to nitrocellulose paper (13) . ApoE and its fragments were detected immunochemically after electrophoretic transfer (Western blotting) (10, 12) . In contrast to HTG-VLDL,, thrombin-treated and trypsin-treated HTG-VLDL, used in these studies no longer suppressed 3-hydroxy-3-methyl-glutaryl-CoA (HMG)-CoA reductase activity in normal human fibroblasts (10, 1 1) nor were they capable of ligand blotting electrophoretically isolated bovine adrenal LDL receptors (13) due to cleavage of the thrombin-accessible apoE by thrombin or total removal of apoE by trypsin, as determined by immunochemical blotting and RIA (10) (11) (12) 26 kD). In this 6% gel system, the latter three proteins were not separated and ran as one band near the dye front.
Results
Competition studies indicate that trypsinized HTG-VLDL devoid ofapoE and HTG-VLDL bind to the same sites on macrophages. Evidence that macrophages possess receptors distinct from the LDL receptor in ligand specificity come from studies that show that apoE is not required for the specific, receptormediated uptake of HTG-VLDL. By contrast, the LDL receptor of cultured human fibroblasts (10) (11) (12) 26) , of murine macrophages (7), or the partially purified receptor from bovine adrenals (13) absolutely requires apoE of an appropriate conformation for binding of large VLDL.
One criterion used as evidence that different particles bind to the same receptor is cross-competition in competitive binding studies. Thus, to determine if apoE was required for the binding of large triglyceride-rich particles to the macrophage receptor, we hydrolyzed HTG-VLDLI with trypsin, to remove all immunochemically detectable apoE and abolish binding to the LDL receptor, for use in competitive binding studies (10) (11) (12) (13) 26) . The removal of apoE of HTG-VLDL by trypsinization was monitored by immunochemical electrophoretic (Western) blotting. No apoE fragments were detected in these experiments (data not shown), as was previously observed (10-13). These same trypsin-treated HTG-VLDLI were tested in two additional ways as controls to show that the LDL receptor binding determinants were indeed lost upon trypsinization. First, as previously established (10) (11) (12) 26) , trypsinization abolished the ability of these HTG-VLDL to suppress HMGCoA reductase activity in cultured human fibroblasts (reductase suppression being a sensitive indicator of receptor-mediated uptake of the lipoprotein). Second, these trypsinized HTG-VLDLI failed to bind directly to DEAE cellulose-purified bovine LDL receptors as determined by ligand blotting, as previously reported (13) .
As seen in Fig. 1 HTG-VLDL,, of '251-trypsinized-HTG-VLDL1, and of control (buffer incubated) '25I-HTG-VLDL, (Fig. 2) . Six separate competition studies with HTG-VLDL, from four different hypertriglyceridemic subjects demonstrated that trypsinized HTG-VLDL, and native HTG-VLDL, competed for the same binding sites on P388D, macrophages.
The similar cross-competitiveness of HTG-VLDL, and trypsinized HTG-VLDL, for binding to macrophages suggests that these lipoproteins bind to equivalent sites. The demonstration that HTG-VLDL compete as efficiently after removing some apoE in thrombin-treated HTG-VLDL (2) rion for receptor binding is that the binding curves exhibit a high affinity component (curvilinearity) as opposed to low affinity binding only (linearity). Direct binding studies were undertaken to exclude the possibility that the competition observed in Fig. 1 by trypsinized VLDL was nonspecific and due to a marked increase in nonspecific adsorption to cells after trypsinization. Direct binding studies at 4VC of iodinated lipoproteins demonstrate that both trypsinized HTG-VLDLI and HTG-VLDLI bind to macrophages in a high affinity, curvilinear manner, indicative of receptor binding (Fig. 3) .
The binding of iodinated trypsinized HTG-VLDL in the absence of unlabeled VLDL (total binding) to macrophages was similar to that of native 251I-HTG-VLDL1 (Fig. 3 Partial or total removal of apoE from HTG-VLDL, does not diminish the massive, rapid, saturable triglyceride accumulation induced by HTG-VLDL, in P388D, macrophages. A third criterion for receptor binding is that binding ofthe ligand to the receptor triggers a physiologic response in the cell. Receptor-mediated uptake of HTG-VLDL at physiological concentrations by macrophages leads to a massive, rapid, curvilinear accumulation of intracellular triglyceride after uptake, lysosomal hydrolysis, and reesterification in murine peritoneal (1) or P388D1 macrophages (2) . As shown in Fig. 4 , trypsinized HTG-VLDL, devoid of apoE and native HTG-VLDL, produce similar triglyceride accumulation. As is also shown, thrombin-treated HTG-VLDL were also as effective as native HTG-VLDL, in stimulating rapid, saturable triglyceride engorgement. HTG-VLDL, treated with hirudin-inactivated thrombin indicates that thrombin, ifpresent in the VLDL, had no effect on triglyceride accumulation.
The failure ofthrombin-and trypsin-treatment to diminish the rapid, saturable triglyceride accumulation in macrophages induced by HTG-VLDL, while abolishing its interaction with LDL receptors, is highly reproducible. Triglyceride accumulation experiments with similar results have been performed seven times with five trypsinized HTG-VLDL1 preparations from four hypertriglyceridemic subjects and with five preparations of thrombin-treated HTG-VLDL, from four hypertriglyceridemic subjects. In no case was the protease-treated HTG-VLDL less effective than native HTG-VLDL in stimulating cellular triglyceride accumulation.
These studies demonstrate that the apoE required for binding of HTG-VLDL, to the LDL receptor, the thrombin-acces- Conversely, labeled HTG-VLDL was effectively competed by itself (Fig. 7, lanes 2 and 3) , by unlabeled trypsinized HTG-VLDL (Fig. 7, lane 5) , and by unlabeled trypsinized normal VLDL (Fig. 7, lane 6) . By contrast, unlabeled LDL failed to compete with the binding of HTG-VLDL to MBP 190 even at a 20-fold excess particle concentration (Fig. 8, lanes 4 and 5) , when only a 3-to 10-fold excess of trypsinized VLDL competed effectively (Fig. 8, lanes 2 and 3) . This lack of effective competition by LDL for MBP 190 is consistent with the ineffective competition of LDL for the cellular uptake and degradation of HTG-VLDL by macrophages previously reported (1, 2). The binding of '251-HTG-VLDL, to MBP 190 was also competed by f,-VLDL at a 10-fold but not at a 3-fold particle excess (data not shown), consistent with previous observations that fp-VLDL competed for the uptake of HTG-VLDL by murine peritoneal (2) and P388D, macrophages (3) . The VLDL, (Fig. 9, left) . Likewise, these preincubations had no effect on the nonspecific uptake of trypsinized VLDL, that is, the amount of iodinated VLDL taken up in the presence of an excess amount of unlabeled VLDL (Fig. 9, middle) specific uptake, that is, total uptake of iodinated trypsinized VLDL in the absence of unlabeled trypsinized VLDL, minus nonspecific uptake, was similar whether or not the cells had been preincubated in lipoprotein-deficient serum or preincubated with 25-hydroxycholesterol and cholesterol (Fig. 9,  right) .
In contrast, as shown in Fig. 10 , the macrophage uptake of iodinated ,-VLDL isolated from cholesterol-fed rabbits is increased by preincubation of the cells in lipoprotein-deficient serum and is decreased by cholesterol loading, consistent with uptake of this lipoprotein being mediated predominantly by the regulatable LDL receptor. This is true for total uptake (Fig.  10, left) and for specific receptor-mediated uptake (Fig. 10,  right) . Nonspecific uptake was similar in the three groups of cells (middle).
The dramatically different regulation of uptake of tryp-VLDL and ,(-VLDL in whole cells studies is reflected in ligand blots of extracts of the three groups of cells (Fig. 1r1) . HTG-VLDL was used as a ligand to visualize all lanes since it binds efficiently both to the LDL receptor (10) (11) (12) (13) Typically, MBP 190 partitions prmarily into the aqueous phase (Fig. 11, lanes 2-4) and the macrophage LDL receptor partitions pimarly into the detergent phase (Fig. 11, lane 7; reference 33), although occasionally some LDL receptor spills over into the aqueous phase of extracts of induced cells (Fig.   1e1, lane 4) . The relative intensities of MBP 190 in lanes 2-4 of Fig. 11 were equivalent, as judged by visual inspection, indicating that expression of MBP 190 was not regulated by these three different preincubations. In contrast, as can be seen in the detergent phase extracts (Fig. 11, lanes 5-7) , the murine macrophage LDL receptor was induced by preincubation of the cells in lipoprotein-deficient serum for 24 h (Fig. 11, lane  7) . At approximately equal protein concentrations, the LDL receptor was not detected in extracts of cells grown in the presence of complete medium containing serum (Fig. 1 1, lane  5) , or in extracts of cells preincubated with 25-hydroxycholesterol and cholesterol ( Fig. 1 1, lane 6) . Exactly the same pattern of induction of the macrophage LDL receptor was observed when 125-I-#-VLDL was used as a ligand; however, #l-VLDL bound better to the LDL receptor than to MBP 190, indicating 3l-VLDL has a higher affinity for the LDL receptor than for MBP 190 (data not shown).
In four different regulatory experiments neither MBP 190 nor cellular uptake of tryp-VLDL increased upon incubation with LPDS, in contrast to the LDL receptor. Conversely, cellular uptake of tryp-VLDL and the expression of MBP 190 showed little to no downregulation after cholesterol loading, conditions that efficiently decreased the LDL receptor and cellular uptake of /-VLDL. These experiments also demonstrate that the P388D1 macrophage LDL receptor appears similar to the bovine LDL receptor in apparent relative molecular mass (Fig. 11, lanes I and 7) and, like the bovine LDL receptor, binds HTG-VLDL (Fig. 11) but not trypsinized HTG-VLDL (not shown).
MBP 190 is immunologically distinctfrom the LDL receptor. Polyclonal antibodies were produced against the purified Figure 11 . Effects of preincubation of macrophages in serum, lipoprotein-deficient serum, or with cholesterol plus 25-hydroxycholesterol on the expression of the LDL receptor and MBP 190. P388D, cells were grown in 100 mm dishes (20 dishes per experimental group) in complete medium for 24 h, washed, and then incubated for 24 h in complete medium containing serum (S), lipoprotein-deficient serum (-C), or in complete medium plus cholesterol (16 sg/ml) and 25-hydroxycholesterol (1I ,g/ml) (+C). The cells were harvested and extracted with Triton X-1 14 and the extracts phase separated as described in Methods. Aliquots of aqueous phase extracts (A, lanes 2-4) and detergent phase extracts (D, lanes 5-7) and the DEAE-cellulose-purified bovine adrenal LDL receptor as a marker (lane 1) were electrophoresed on a 6% polyacrylamide gel. After electrophoresis, proteins were transferred to nitrocellulose, blocked, incubated with 1251-HTG-VLDL, 20 ,g/ml, dried, and exposed to x-ray film for 16 h. Mobilities of the prestained relative molecular mass standards are indicated.
Apolipoprotein E-independent Macrophage Receptorfor Lipoproteins 1639 -LDLR Er-mof .II bovine adrenal LDL receptor and the IgG fraction was purified and tested for its ability to block binding of lipoproteins to the LDL receptor and to MBP 190 in ligand blot analyses. The LDL receptor from the bovine adrenal cortex and macrophage Triton X-114 aqueous phase extracts were electrophoresed and transferred to nitrocellulose (Fig. 12 ). The nitrocellulose strips were then preincubated with either preimmune IgGs or with the anti-LDL receptor IgGs and then with labeled ligand. The anti-LDL receptor IgGs effectively blocked binding of HTG-VLDL to the LDL receptor (Fig. 12, lane 1) . In contrast, the anti-LDL receptor IgGs failed to block binding of trypsinized VLDL to MBP 190 (Fig. 12, lane 3) . Control preimmune IgGs did not block binding of HTG-VLDL to the LDL receptor (Fig. 12, lane 2) , or tryp-VLDL to MBP 190 (Fig. 12, (Fig. 13 A) . Likewise, control nonimmune IgGs had no effect on uptake. In sharp contrast, the anti-LDL receptor IgGs, but not nonimmune IgGs, effectively blocked the specific uptake of t251 -f3-VLDL by P388D, macrophages with upregulated LDL receptors (Fig. 13 B) , indicating these anti-LDL receptor IgGs block uptake via the murine macrophage LDL receptor. These experiments provide further evi- (Fig. 14, lanes 3 and 5) . For comparison, MBP 190 from P388D1 macrophages (Fig. 14, lanes 2 and 4) and the bovine LDL receptor (Fig. 14, lane 1) are shown. In human monocyte extracts, two proteins that bind HTG-VLDL and trypsinized HTG-VLDL are evident (Fig. 14, lanes 3 and 5, respectively) blasts do not express a high affinity receptor pathway for trypSinized VLDL (10, 11, 26) . Moreover, ligand blots indicate that cultured human skin fibroblasts do not possess a binding protein similar to MBP 190 or any protein that binds trypsinized HTG-VLDL in either aqueous or detergent-phase Triton X-1 14 extracts or in octylglucoside extracts (data not shown). Thus, the 190-kD binding protein appears to be present in human monocytes and murine macrophages that take up human triglyceride-rich lipoproteins by a high affinity pathway, but not in a nonmacrophage cell type such as the cultured human skin fibroblast that, however, can express high levels of the LDL receptor. Therefore, the cellular distribution of the -1 90-kD binding protein and high affinity cellular uptake of tryp-VLDL differs from that of the ubiquitous LDL receptor pathway.
Discussion
Previous and current evidence indicates that macrophages have an alternate receptor pathway for abnormal human triglyceride-rich lipoproteins distinct from the LDL receptor. First, direct and competitive binding, uptake, degradation, and triglyceride accumulation studies indicate that the ligand specificity of the macrophage receptor is distinct from that of the LDL receptor: apoE is not necessary for the binding of triglyceride-rich particles to the macrophage receptor, but is essential for binding to the LDL receptor, including the murine macrophage receptor (7, 10-13, 17, 26 1-3, 5) , and thrombin-or trypsin-treated HTG-VLDL (1-3, and this report) as well as to MBP 190, suggesting apoC peptides are not required for binding. Since each of the native and protease-modified human lipoproteins that bind to MBP 190 and are internalized via the alternate macrophage receptor pathway minimally contains apoB or apoB fragments, we suggest that one or more domains of apoB are involved in binding. These domain(s) would be expressed in lipoproteins that bind to this receptor (plasma chylomicrons, HTG-VLDL, thrombin-treated HTG-VLDL, and trypsin-treated normal and HTG-VLDL) but not in the apoB-containing lipoproteins that do not bind with high affinity to the receptor (normal VLDL and LDL). Since the lipoproteins that bind contain apoB species or fragments in addition to apoB-100, in contrast to normal VLDL and LDL, a domain expressed normally or after degradation of apoB may be involved in binding of these lipoproteins (10 , 1 1).
An alternate and distinct macrophage receptor pathway for abnormal triglyceride-rich lipoproteins is potentially important in clinicopathologic phenomena such as in the accumulation of foam cells in hypertriglyceridemic diabetics (35) , in the development of premature atherosclerosis associated with certain hypertriglyceridemias (21) , and'in the increased incidence of myocardial infarction associated with hypertriglyceridemia (36, 37) . Uptake of abnormal triglyceride-rich lipoproteins by this alternate macrophage receptor pathway may be involved in the conversion of macrophages into lipid-filled foam cells that accumulate in some forms of hypertriglyceridemia (21) . The presence of MBP 190-like binding proteins for HTG-VLDL in human monocytes underscores the potential role of this pathway in humans. Moreover, the maximal binding, uptake, degradation, and triglyceride accumulation in macrophages via the distinct macrophage receptor observed in vitro occur at or below the HTG-VLDL1 levels that are found in the plasma of many hypertriglyceridemic subjects. Thus there is sufficient HTG-VLDL1 present in these subjects' plasma to saturate these receptors present on monocytes or macrophages.
Observations in diabetic subjects support the possibility that these phenomena can occur in vivo. Triglyceride-rich foam cells are found in eruptive xanthomas in untreated hypertriglyceridemic (type 5) diabetics (35) . Insulin treatment of these subjects results in a lowering ofplasma triglyceride levels, after which the triglycerides in the foam cells rapidly diminish, leaving cholesterol as the predominant lipid (35) . A similar process could occur in the genesis of arterial foam cells in hypertriglyceridemic subjects, many of whom suffer from premature atherosclerosis.
